InvestSMART

Resonance Health Limited (ASX: RHT) - Announcements

Current share price for RHT : $0.078 0.002 (2.63%)+

ASX company news and announcements for Resonance Health Limited (RHT) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Resonance Health Limited (RHT) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Resonance Health Limited (RHT), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Resonance Health Limited (RHT)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$37 Preliminary Final Report 30 Aug 2018 2:57PM $0.023 $0.078 risen by 239.13%
$37 Additional Information on Announcement Dated 23 August 2018 27 Aug 2018 1:43PM $0.023 $0.078 risen by 239.13%
$37 Trading Halt 27 Aug 2018 9:00AM $0.023 $0.078 risen by 239.13%
$37 Resonance Health contracted for two new clinical trials 23 Aug 2018 3:02PM $0.021 $0.078 risen by 271.43%
$37 Appendix 4C - quarterly 23 Jul 2018 10:21AM $0.022 $0.078 risen by 254.55%
$37 TGA, CE Mark clearance for A.I. Solution FerriSmart 11 Jul 2018 8:58AM $0.021 $0.078 risen by 271.43%
$37 Alliance Partner Agreement with Blackford Analysis 5 Jul 2018 1:49PM $0.023 $0.078 risen by 239.13%
$37 Customer Newsletter - June 2018 29 Jun 2018 4:08PM $0.024 $0.078 risen by 225%
$37 Investor Presentation June 2018 12 Jun 2018 8:23AM $0.022 $0.078 risen by 254.55%
$37 Change of Director's Interest Notice 31 May 2018 5:35PM $0.024 $0.078 risen by 225%
$37 Change of Director's Interest Notice 29 May 2018 12:03PM $0.023 $0.078 risen by 239.13%
$37 Additional Info. in relation to 4 May 2018 announcement 4 May 2018 5:47PM $0.027 $0.078 risen by 188.89%
$37 Resonance Deal to distribute Diabetic Retinopathy AI tool 4 May 2018 1:10PM $0.023 $0.078 risen by 239.13%
$37 Appendix 4C - quarterly 23 Apr 2018 4:07PM $0.022 $0.078 risen by 254.55%
$37 Customer Newsletter - March 2018 23 Mar 2018 4:27PM $0.022 $0.078 risen by 254.55%
$37 Appendix 3B 9 Mar 2018 4:32PM $0.024 $0.078 risen by 225%
$37 Change of Director's Interest Notice 7 Mar 2018 3:35PM $0.024 $0.078 risen by 225%
$37 Director Appointment 28 Feb 2018 4:13PM $0.025 $0.078 risen by 212%
$37 Half Yearly Report and Accounts 26 Feb 2018 3:11PM $0.025 $0.078 risen by 212%
$37 Appointment of CEO 23 Feb 2018 2:57PM $0.025 $0.078 risen by 212%
$37 RHT Develops new assessment for the screening of NASH 20 Feb 2018 1:31PM $0.022 $0.078 risen by 254.55%
$37 Change of Director's Interest Notice 15 Feb 2018 2:08PM $0.022 $0.078 risen by 254.55%
$37 Resonance Health contracted for new clinical trial 13 Feb 2018 8:16AM $0.023 $0.078 risen by 239.13%
$37 R&D Tax Incentive 9 Feb 2018 3:00PM $0.021 $0.078 risen by 271.43%
$37 Appendix 4C - quarterly 31 Jan 2018 10:02AM $0.022 $0.078 risen by 254.55%

276 - 300 of 534 results

Page 12 of 22

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.